News on hematology and coagulation testing systems and applications.
The company's full-year revenues rose 6 percent and were slightly higher than the consensus Wall Street estimate.
The ID Core XT is the second molecular assay approved by the FDA for use in transfusion medicine and the first to report genotypes as final results.
The company's Life Sciences segment was up 17 percent year over year, while its Diagnostics business grew 8 percent.
The test reduces hands-on time by enabling labs to simultaneously assess Factor II and Factor V gene mutations from a single patient sample, Roche said.
The company said that the funds will allow it to take its ReadyPlex rapid blood group genotyping assays into clinical trials and commercialization.
